Trend — Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram (J7677) in Medicare, the United States

The full twelve-year services and payments series for this market — per-year values, with the FFS-enrollment denominator beside each.

The compound annual growth for J7677 in the United States — endpoints exclude the introduction year; an Exclude 2020–21 view drops the pandemic years too.